Halozyme Therapeutics Inc
$ 66.28
-2.73%
02 Jun - close price
- Market Cap 8,082,290,000 USD
- Current Price $ 66.28
- High / Low $ 67.44 / 65.59
- Stock P/E 23.91
- Book Value 1.85
- EPS 2.85
- Next Earning Report 2026-08-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.22 %
- ROE 0.99 %
- 52 Week High 82.22
- 52 Week Low 51.06
About
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company is headquartered in San Diego, California.
Analyst Target Price
$83.90
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-11 | 2026-02-17 | 2025-11-03 | 2025-08-05 | 2025-05-06 | 2025-02-18 | 2024-10-31 | 2024-08-06 | 2024-05-07 | 2024-02-20 | 2023-11-06 | 2023-08-08 |
| Reported EPS | 1.2212 | -0.24 | 1.72 | 1.54 | 1.11 | 1.26 | 1.27 | 0.91 | 0.79 | 0.82 | 0.75 | 0.74 |
| Estimated EPS | 1.76 | 2.2 | 1.63 | 1.27 | 0.95 | 1.1588 | 0.98 | 0.76 | 0.7 | 0.83 | 0.71 | 0.64 |
| Surprise | -0.5388 | -2.44 | 0.09 | 0.27 | 0.16 | 0.1012 | 0.29 | 0.15 | 0.09 | -0.01 | 0.04 | 0.1 |
| Surprise Percentage | -30.6136% | -110.9091% | 5.5215% | 21.2598% | 16.8421% | 8.7332% | 29.5918% | 19.7368% | 12.8571% | -1.2048% | 5.6338% | 15.625% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-04 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 1.82 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: HALO
2026-06-01 10:19:00
Halozyme Therapeutics, Inc. (HALO) is highlighted as a promising biotechnology company with a unique focus on enhancing drug delivery systems. The analysis points to a potential 26% upside based on analyst ratings, strong financial health with 42.20% revenue growth, and strategic partnerships. Despite a recent minor dip, its valuation metrics, including a forward P/E of 6.73, suggest it may be undervalued, making it an attractive prospect for investors.
2026-05-28 22:39:15
Halozyme has announced its intent to acquire Elektrofi, a biopharmaceutical company specializing in drug delivery. This acquisition is significant as it will integrate Elektrofi's innovative drug delivery technologies into Halozyme's existing portfolio. The move aims to enhance Halozyme's capabilities in the biopharma sector by expanding its drug delivery platforms.
2026-05-28 22:39:15
Halozyme Therapeutics Inc. is set to release its first-quarter earnings, with analysts anticipating a recovery in profitability and strong revenue growth. The company’s ability to sustain momentum in its high-margin royalty business, particularly from its ENHANZE platform and newer Hypercon technology, will be key areas of focus for investors. Despite a prior quarter EPS miss due to an acquisition expense, Halozyme reiterated its 2026 royalty revenue guidance, driven by key drug franchises.
2026-05-28 03:08:52
Halozyme Therapeutics Inc. announced its intention to acquire Elektrofi Inc., a private biopharmaceutical company specializing in drug delivery using its proprietary ultra-high concentration formulation technology. This acquisition is expected to enhance Halozyme's drug delivery portfolio and support its long-term growth strategy.
2026-05-26 13:10:06
Implied volatility for Halozyme Therapeutics (HALO) stock options, particularly the Jun 18, 2026 $40 Call, has surged, indicating that the market expects significant price movement. Analysts currently rate HALO as a Zacks Rank #3 (Hold), with recent downward revisions to earnings estimates. This high implied volatility suggests a potential trading opportunity, possibly for options traders looking to sell premium.
2026-05-21 08:40:12
Halozyme Therapeutics (HALO) has experienced a flat share price recently, but strong long-term returns have drawn investor attention. Despite a P/E ratio higher than the industry average, the stock is considered 20.1% undervalued based on a fair value estimate, with its ENHANZE platform positioned to benefit from the shift towards subcutaneous drug delivery. Investors are encouraged to weigh the data and consider other investment opportunities.
